ANRO Stock Catalyst: Alto Neuroscience Announces $50M Private Placement and Phase 3 Study Plan for ALTO-207

Oct 20, 2025 · 7:01am ET

Company aims to accelerate development in treatment resistant depression.

Max move

+94.1%

High of day $12.19

Sparker timei

7:01am ET

ANRO · Oct 20, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Alto Neuroscience, Inc. (NYSE: ANRO) announced plans to initiate a Phase 3 study of its ALTO-207 drug in treatment resistant depression (TRD) patients by early 2027. Simultaneously, the company revealed a $50 million private placement to fund the accelerated development of ALTO-207.

The private placement will provide Alto Neuroscience with $50 million in funding. The company has 20,754,500 shares in free float.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time ANRO sparks.

Download Sniper App →

Catch the next ANRO-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →